Nkarta, Inc.

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Top-notch Nkarta stock tumbled Friday after the biotech company deprioritized a cancer drug in favor of an experimental lupus treatment.

Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023.

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

SurgePays

Unisys

Some overlooked stocks remain obscure and wait for astute investors to spot them. This happens even in the middle of Wall Street's busy trading floors and the digital chaos of online investing platforms.

3 Overlooked Stocks Ready to Capture the Market by Storm

Nkarta's stock soared 690% in six months, buoyed by promising cell therapy technology for cancer and autoimmune diseases. Financially healthy, with a high current ratio and a cash runway extending into 2026, indicating low near-term dilution risk. Despite high short interest, market sentiment is robust, driven by insider buying and significant institutional investment.

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Palo Alto Networks

Sterling Construction

Among tech investments, the search for the next titan resembles a deep dive into the ocean for pearls. The periodic portfolio shifts toward solid tech contenders with high-yield potential as the digital space evolves.

3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket

Global Ship Lease

Hudson Technologies

RCM Technologies

Silvercorp Metals

Zymeworks Inc

The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are making waves in various industries, offering the chance to capitalize on their leads.

Last Call! 7 Small-Cap Stocks Ready to Explode in Value

Teekay Tankers

In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors.

3 Under-the-Radar Stocks Set to Soar 300% by 2026

Everest Group Ltd

PayPal

Amidst the bustle of large tech giants taking up the artificial intelligence ( AI ) space and news headlines of leading pharmaceutical juggernauts marking key development milestones, many quality stocks can easily fly under an investor's radar. Whether those are smaller companies producing innovative solutions or undervalued companies slowly working toward profitability, there lay hundreds of opportunities for investors that many investors have glazed over.

3 Sleeper Stocks With Serious Potential to Make You a Millionaire

Amphastar Pharma

Arcutis Biotherapeutics

The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.

3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

ACM Research

Clover Health Investments

Some stocks silently position themselves for monumental bursts. These companies, spanning the semiconductor, healthcare and biotechnology sectors, are emerging as unseen giants with the potential for a 10X surge.

Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge

NKTX has seen a significant increase in stock price, recovering from a previous decline following the failure of rival Fate Therapeutics' NK program. NKTX's NK cell-based therapies have shown promising results, including a complete remission rate of 60% in patients with acute myeloid leukemia. The company's focus on a specific lymphodepletion regimen has shown better safety and durability outcomes, positioning them as a leader in the NK cell therapy space.

Nkarta: Possible Upside From H1 Update, If Positive

Delcath Systems

The Oncology Institute

Wave Life Sciences

As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.

Penny Stocks To Buy Now? 4 To Watch Before 2024

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition featuring follow-up data from its Phase 1 clinical trial that evaluates NKX101 in patients with relapsed or refractory acute myeloid leukemia (r/r AML). NKX101 is an allogeneic, off-the-shelf NK cell therapy candidate derived from healthy donors and engineered to target NKG2D ligands.

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2023.

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences:

Nkarta to Participate at Upcoming Investor Conferences

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.

Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

NEW YORK , Oct. 17, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support Nkarta in early development through select sites of the Lupus Clinical Investigators Network (LuCIN) comprised of top academic centers throughout North America.

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m.

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

DURECT

eFFECTOR Therapeutics Inc

For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.

3 Promising Biotech Stocks That Will Make Early Investors Rich

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023.

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at an upcoming investor conference:

Nkarta to Participate at Upcoming Investor Conference

Harte Hanks

Investing in penny stocks can feel like finding needles in a haystack, and can certainly be an uphill battle for most investors. Different from investing in well-established businesses, you can't hold your way to profit with most small businesses.

3 Hidden Penny Stocks That Could Turn $100 into $10,000

News for Nkarta, Inc. Stock (NKTX)